Literature DB >> 10401515

Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence.

S Krishnan-Sarin1, M I Rosen, S S O'Malley.   

Abstract

BACKGROUND: This study used an opioid antagonist challenge procedure to evaluate the responsivity of the endogenous opioid system in nicotine-dependent individuals, as evidenced by naloxone-induced alterations in both behavioral (withdrawal, craving) and neuroendocrine (cortisol levels) parameters.
METHODS: Twenty subjects (9 smokers and 11 nonsmokers) participated in 4 laboratory sessions during which they were challenged with 0, 0.8, 1.6, or 3.2 mg/70 kg of naloxone and then monitored for 1 hour for subjective signs and symptoms of opiate-like withdrawal, nicotine craving, and alterations in cortisol levels.
RESULTS: Nicotine-dependent subjects evidenced naloxone dose-dependent increases in withdrawal signs and symptoms. Lower doses of naloxone also produced increases in urges to smoke (craving) and tiredness in smokers. Smokers, when compared with nonsmokers, had lower prenaloxone baseline levels of cortisol and attenuated cortisol release in response to challenge with naloxone.
CONCLUSIONS: These results provide preliminary evidence to suggest that long-term exposure to cigarette smoke is associated with alterations in the responsivity of the endogenous opioid system and the hypothalamic-pituitary-adrenal axis that may contribute to the development of nicotine dependence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401515     DOI: 10.1001/archpsyc.56.7.663

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  34 in total

Review 1.  Current concepts in pharmacotherapy of substance abuse.

Authors:  P C Gottschalk; L K Jacobsen; T R Kosten
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  Predictors of Tobacco Use Among New York State Addiction Treatment Patients.

Authors:  Joseph Guydish; Jiang Yu; Thao Le; Anna Pagano; Kevin Delucchi
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

3.  Attenuated beta endorphin response to acute stress is associated with smoking relapse.

Authors:  Darcy Shaw; Mustafa al'Absi
Journal:  Pharmacol Biochem Behav       Date:  2008-04-03       Impact factor: 3.533

4.  Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial.

Authors:  Adam Bress; Rick Kittles; Coady Wing; Stanley E Hooker; Andrea King
Journal:  Pharmacogenet Genomics       Date:  2015-06       Impact factor: 2.089

5.  Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Authors:  Andrés P Varani; Ester Aso; Lirane Machado Moutinho; Rafael Maldonado; Graciela N Balerio
Journal:  Psychopharmacology (Berl)       Date:  2014-02-20       Impact factor: 4.530

6.  Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.

Authors:  Rosemarie A Martin; Damaris J Rohsenow; Jennifer W Tidey
Journal:  J Subst Abuse Treat       Date:  2019-06-10

7.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

8.  Coadministration of intravenous nicotine and oral alcohol in rats.

Authors:  A D Lê; Steven Lo; Stephen Harding; Walter Juzytsch; Peter W Marinelli; Douglas Funk
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

9.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

10.  Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.

Authors:  Andrea King; Dingcai Cao; Lingjiao Zhang; Sandra Yu Rueger
Journal:  Addiction       Date:  2013-07-12       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.